The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
The prospective, multicenter LOCATE trial assessed the impact of positron emission tomography/computed tomography (PET/CT) with 18F-fluciclovine on management plans for patients with biochemical recurrence (BCR) of prostate cancer after curative-intent primary therapy.
Men who had undergone curative-intent treatment of histologically confirmed prostate cancer, but who were suspected to have recurrence based on rising prostate-specific antigen (PSA) levels, were enrolled prospectively. Each had negative or equivocal findings on standard-of-care imaging. 18F-Fluciclovine-PET/CT was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient's management plan pre- and post-scan, recording changes to treatment modality (e.g., salvage radiotherapy to systemic androgen deprivation therapy) as 'major', and changes within a modality (e.g., modified radiotherapy fields) as 'other'.
Between June 2016 and May 2017, 213 evaluable patients (median age 67 years; median PSA 1.00 ng/mL) were enrolled. 18F-Fluciclovine-avid lesions were detected in 122/213 (57%) patients. Overall, 126/213 patients (59%) had a change in management post-scan; 98/126 (78%) of these were 'major' and 88/126 (70%) were informed by positive PET/CT findings. The most frequent major changes were from salvage or non-curative systemic therapy to watchful waiting (32/126, 25%), from non-curative systemic therapy to salvage therapy (30/126, 24%) and from salvage therapy to non-curative systemic therapy (11/126, 9%).
18F-Fluciclovine-PET/CT detected one or more sites of recurrence in the majority of men with BCR, frequently resulting in major changes to their management plans. Future studies will be planned to determine if change of management leads to improved outcomes.
This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2024.
All research outputs
#1,121,190
of 34,457,357 outputs
Outputs from The Journal of Urology
#604
of 21,144 outputs
Outputs of similar age
#20,462
of 487,470 outputs
Outputs of similar age from The Journal of Urology
#5
of 174 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 21,144 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 487,470 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 174 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.
